Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Cystathionase Regulated By Farnesoid X Receptor
The expression and activity of Cystathionase is reduced in rodent models of liver injury, leading to hyper-homocysteinemia and impaired generation of hydrogen sulphide, two factors that contribute to endothelial dysfunction and increased intrahepatic resistance.
generic viagra online
National Survey Looks At HIV/AIDS In South Africa
According to the results of a national survey conducted in 2008 and released Tuesday, HIV prevalence among South Africans between the ages of 15 and 24 dropped from "a high of 10.3 percent in 2005 to 8.7 percent last year, with the decreases most marked among teenagers," AFP/Google.com reports (AFP/Google.com, 6/9). The Telegraph writes, "HIV prevalence in children between 2 and 14 fell from 5.6 per cent in 2002 to 2.5 per cent last year, mainly thanks to the spread of drugs to prevent women passing on the virus to their children" (Telegraph, 6/10). Drugshop to buy zoloft online and other pills.
News of the day
UC Davis Researchers Develop New Test For Fragile X Syndrome
Researchers at UC Davis have developed a new test that will measure the protein deficit responsible for fragile X syndrome - the single-most common cause of intellectual impairment and the most-commonly inherited cause of autism. The test, described in a study appearing online in the July 2009 issue of The Journal of Molecular Diagnostics, is the first to measure an individual"s level of the fragile X mental retardation 1 (FMR1) protein.
Medical Devices

Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data For AM211, A Novel Product Candidate For The Treatment Of Respiratory Diseases

Amira Pharmaceuticals, Inc. announced initial positive data from a Phase 1 clinical study of AM211, the company"s oral selective antagonist of the DP2 (also known as CRTH2) receptor. The interim results demonstrate that a sustained pharmacodynamic (PD) effect can be achieved with a single dose of AM211. The pharmacokinetic profile indicates safety multiples as compared to exposures observed in safety species. While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for this target to be a novel treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. "The AM211 clinical PD data confirms what we previously observed in pre-clinical models," said Isabelle DeArmond, M.D., Vice President, Clinical Development. "While a great deal of clinical work remains on this program, we are particularly excited since we believe DP2 antagonism would be a novel therapeutic approach to various respiratory diseases." Bob Baltera, Chief Executive Officer, added, "Once again the Amira team demonstrates our ability to quickly, efficiently and accurately translate scientific efforts into meaningful therapeutic candidates. The fact that we now have clinical data only 25 months after we initiated scientific efforts on this target in our laboratories is a of pride for the entire Amira team." About Amira Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. Amira Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009